ENSr Medical

What ENSr Medical does

ENSr Medical, Inc. is a privately held medical device company founded in Chicago in 2013 that develops handheld, non-invasive neuromodulation devices for drug-free management of acute, chronic, and post-operative pain. The core technology delivers targeted nerve stimulation intended to support the body's natural pain-regulation and self-healing mechanisms, positioned as an alternative to pharmacological treatments, needles, and surgery. The company states its devices are FDA and EU-cleared (with active regulatory pursuit ongoing) and targets patients seeking drug-free relief, healthcare providers and medical practices, and the sports medicine/athletic performance segment, supported by a Medical Director who served as team physician for four US Olympic Teams and a Director of Sports Medicine who has treated MLB and NHL franchises.

The company operates a hardware sales revenue model through an enterprise field sales motion, combining direct sales to healthcare providers with an international distribution and reseller network spanning Chicago, New York, the Netherlands, and Australia, alongside historical market development across South Africa, the Middle East, Latin America, and parts of Asia via predecessor distribution companies. The leadership team is led by co-founder and CEO Helen L'Huede, who brings 20+ years of neuromodulation experience and prior board service with Chronic Pain Australia, supported by co-founder Elle Murphy (VP Corporate Development) and a recently added VP of Sales and Marketing with 25+ years of business and consulting experience, indicating a transition from founder-led R&D toward a structured commercial buildout.

ENSr Medical is founder-led, privately held, and bootstrapped per available data, with no disclosed institutional investors, no reported funding beyond a single $10,000 round in September 2013, no disclosed revenue, and no acquisitions or subsidiaries. The principal gating event for the business remains regulatory clearance, after which the established international footprint, sports medicine credibility, and enterprise sales infrastructure are positioned to support commercial launch across multiple geographies.

Name

ENSr Medical

Legal name

ENSr Medical, Inc.

Website

https://ensrmedical.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

ENSr Medical is a private, Chicago-based medical device company founded in 2013 that develops handheld, non-invasive neuromodulation devices for drug-free pain management, targeting healthcare providers, medical practices, professional sports franchises, and patients seeking alternatives to pharmacological pain treatment.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices) (CRACAQAK)

akta.pro secondary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

Keywords

• Non-invasive pain management
• Neuromodulation medical devices
• Drug-free pain relief
• Handheld pain therapy
• Post-operative pain treatment

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Sale of FDA and EU-cleared handheld non-invasive medical devices for pain management. The company is on track to produce handheld devices designed to eliminate or manage pain for a wide range of pain diagnoses.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

ENSr Medical develops and manufactures handheld, FDA and EU-cleared non-invasive medical devices that use advanced neuromodulation technology to deliver targeted nerve stimulation for drug-free pain relief. The devices are designed to eliminate or manage acute, chronic, and post-operative pain without reliance on medications, needles, or surgery, and are intended for deployment through healthcare providers, medical practices, and major medical centers.

Product overview

ENSr Medical offers a single core product: handheld, FDA and EU-cleared non-invasive medical devices for drug-free pain management. Their technology is based on advanced neuromodulation that delivers targeted nerve stimulation to help regulate and manage pain. The devices are designed to help the body's natural self-healing and pain-regulation mechanisms without reliance on medications, needles, or surgery. The company is actively pursuing FDA clearance and follows established regulatory pathways.

Differentiator

Problem solved

Functional benefit

Products and services

• ENSr Medical Non-Invasive Pain Management Device

Quantifiable outcome

• Drug-free pain management reducing reliance on pharmacological treatments
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Chronic Pain AustraliacoreStrategic or Co-development PartnerHelen L'Huede served for two years on the Board of Chronic Pain Australia, one of five organizations that developed Australia's National Pain Strategy. This partnership demonstrates the company's commitment to advancing pain management policy and patient-centered care approaches at the national level.
• Medical Practices and Major Medical CenterscoreStrategic or Co-development PartnerEstablished early relationships with medical practices and major medical centers for deploying the company's pain management technology. These healthcare institutions represent key partnerships for clinical validation and market adoption of the technology.
• Nationally Recognized Charitable OrganizationminorGTM or Marketing PartnerEstablished early relationships with a nationally recognized charitable organization as part of market development and community outreach efforts.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• NeuroMetrix: Public developer of Quell, a non-invasive wearable neuromodulation device for chronic pain, making it the closest direct competitor to ENSr's handheld non-invasive pain neuromodulation platform.
• Cefaly: Markets a non-invasive external trigeminal nerve stimulation (eTNS) device for migraine and pain relief, directly competing in the handheld, non-invasive, drug-free neuromodulation category.
• Cala Health: Develops wearable non-invasive neuromodulation therapy devices (initially for essential tremor, expanding into pain), positioning it as a direct peer in non-invasive, prescription neuromodulation hardware.
• electroCore: Sells gammaCore, a non-invasive vagus nerve stimulation device cleared for headache and pain indications, directly comparable to ENSr's handheld, non-invasive, drug-free regulatory positioning.
• iReliev: Sells consumer and clinical TENS/EMS pain-relief devices, comparable to ENSr on handheld form factor, non-invasive electrical stimulation, and drug-free pain management positioning.
• CyMedica Orthopedics: Markets neuromuscular electrical stimulation (NMES) systems for post-operative and orthopedic pain and recovery, overlapping with ENSr's post-operative and orthopedic pain use cases.

Broad incumbents

• Medtronic: Global leader in implantable spinal cord stimulation (Intellis) and DBS for chronic pain and movement disorders; the dominant incumbent in the broader neuromodulation category where ENSr competes non-invasively.
• Abbott: Markets the Proclaim DRG and BurstDR neurostimulation systems for chronic and post-surgical pain, representing a major incumbent with deep clinical evidence and reimbursement infrastructure.
• Boston Scientific: Sells the WaveWriter and Spectra spinal cord stimulator portfolios for chronic pain, providing incumbent scale and physician relationships that shape the broader neuromodulation market ENSr targets.
• Axonics: Markets sacral and tibial neuromodulation systems with expanding indications into pain-related disorders, serving as a fast-growing incumbent in adjacent neuromodulation segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ensrmedical
• Facebookfacebook.com/ensrinc
• LinkedInlinkedin.com/company/ensr-medical-inc-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENSr Medical